title: Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor: an analysis of a series of 42 lymphadenectomies.
abstract: BACKGROUND
  The aim of this study is to evaluate the rate and the clinical outcomes of lymph node involvement in patients treated for borderline ovarian tumor (BOT).
  
  
  METHODS
  Forty-two patients were treated for BOT with a procedure that included lymphadenectomy. Twenty-four patients underwent a pelvic lymphadenectomy, 6 a paraaortic lymphadenectomy, and 12 both procedures. Thirty-two patients underwent systematic lymphadenectomy, five because of associated cancer (uterine cervix or corpus) and five because of bulky nodes discovered during the surgical procedure.
  
  
  RESULTS
  An endosalpingiosis was present in 11 (26%) patients who underwent lymphadenectomy. Eight patients had nodal involvement related to the BOT. All patients with nodal involvement had serous BOT with peritoneal implants. None of the patients with a mucinous tumor had nodal involvement. None of the patients with early-stage disease (without peritoneal disease) had nodal involvement discovered after routine lymphadenectomy. None of the patients with nodal involvement died of borderline tumor. One patient died of a complication of adjuvant therapy (leukemia after chemotherapy).
  
  
  CONCLUSIONS
  The prognosis of patients with borderline tumors of the ovary and nodal involvement is excellent. Routine lymphadenectomy should not be performed in patients with early-stage disease. This procedure should be carried out in patients with serous tumor and enlarged lymph nodes.
authors.forename: Sophie
authors.initials: S
authors.lastname: Camatte
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
authors.forename: David
authors.initials: D
authors.lastname: Atallah
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
authors.forename: Christine
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Damienne
authors.initials: D
authors.lastname: Castaigne
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D018291:Cystadenoma, Mucinous / Q000473:pathology / Q000628:therapy; D018293:Cystadenoma, Serous / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008875:Middle Aged; D009367:Neoplasm Staging; D018193:Neoplasms, Complex and Mixed / Q000473:pathology / Q000628:therapy; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis